Literature DB >> 16556765

Low insulin-like growth factor binding protein-2 expression is responsible for increased insulin receptor substrate-1 phosphorylation in mesangial cells from mice susceptible to glomerulosclerosis.

Alessia Fornoni1, Steven A Rosenzweig, Oliver Lenz, Ana Rivera, Gary E Striker, Sharon J Elliot.   

Abstract

Mesangial cells (MC) isolated from glomerulosclerosis-prone ragged, olygosyndactilism, pintail (ROP) mice retain a stable phenotype after exposure to elevated glucose concentrations, whereas MC from glomerulosclerosis-resistant C57BL/6 (C) mice do not. In NOD and db/db mice, the stable phenotype induced by diabetes consists of autocrine activation of the IGF-I signaling pathway. We hypothesized that high ambient glucose activates the IGF-I pathway in ROP but not in C MC. MC were propagated in either 6 or 25 mm glucose. Isolated murine glomeruli were used to confirm in vitro experiments. 25 mm glucose induced increased insulin receptor substrate (IRS)-1 phosphorylation in ROP but not C MC. However, IGF-I, IGF-I receptor, and IRS-1 protein levels were induced by exposure to 25 mm glucose in both cell lines. This occurred without a change in IGF-I binding sites, suggesting a role for IGF binding protein (IGFBP). ROP MC and glomeruli expressed less IGFBP-2 than C MC and glomeruli. Addition of exogenous IGFBP-2 partially blunted the effect of 25 mm glucose on IRS-1 phosphorylation in ROP MC. Renal biopsies from patients with diabetic nephropathy also showed markedly decreased IGFBP-2 expression when compared with patients without nephropathy. In summary, glucose induces IRS-1 phosphorylation in MC isolated from ROP mice susceptible to glomerulosclerosis. IGFBP-2 expression was low in ROP MC and glomeruli from patients with diabetic nephropathy, suggesting that this may represent a new marker of susceptibility to diabetic nephropathy. Finally, addition of exogenous IGFBP-2 in ROP MC partially blunted the effect of high glucose on IRS-1 phosphorylation and might have a protective role.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16556765     DOI: 10.1210/en.2006-0066

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  7 in total

1.  Hepatic leptin signalling and subdiaphragmatic vagal efferents are not required for leptin-induced increases of plasma IGF binding protein-2 (IGFBP-2) in ob/ob mice.

Authors:  J Levi; F K Huynh; H C Denroche; U H Neumann; M M Glavas; S D Covey; T J Kieffer
Journal:  Diabetologia       Date:  2011-12-28       Impact factor: 10.122

2.  Maternal nutritional history modulates the hepatic IGF-IGFBP axis in adult male rat offspring.

Authors:  Timothy Smith; Deborah M Sloboda; Richard Saffery; Eric Joo; Mark H Vickers
Journal:  Endocrine       Date:  2013-08-21       Impact factor: 3.633

3.  Angiotensin II- and glucose-stimulated extracellular matrix production: mediation by the insulin-like growth factor (IGF) axis in a murine mesangial cell line.

Authors:  Lori K Davis; Buel D Rodgers; Kevin M Kelley
Journal:  Endocrine       Date:  2008-04-08       Impact factor: 3.633

Review 4.  Role of altered insulin signaling pathways in the pathogenesis of podocyte malfunction and microalbuminuria.

Authors:  Alexandra Jauregui; Daniel H Mintz; Peter Mundel; Alessia Fornoni
Journal:  Curr Opin Nephrol Hypertens       Date:  2009-11       Impact factor: 2.894

5.  In vitro silencing of the insulin receptor attenuates cellular accumulation of fibronectin in renal mesangial cells.

Authors:  Naohiro Yano; Daisuke Suzuki; Masayuki Endoh; Weizhi Zhang; Yan Chun Xu; James F Padbury; Yi-Tang Tseng
Journal:  Cell Commun Signal       Date:  2012-10-12       Impact factor: 5.712

Review 6.  IRS proteins and diabetic complications.

Authors:  Deborah P Lavin; Morris F White; Derek P Brazil
Journal:  Diabetologia       Date:  2016-08-11       Impact factor: 10.122

Review 7.  Growth Hormone and IGF1 Actions in Kidney Development and Function.

Authors:  Evgenia Gurevich; Yael Segev; Daniel Landau
Journal:  Cells       Date:  2021-11-30       Impact factor: 6.600

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.